Human leukocyte Ig-like receptor B1 (LILRB1) and B2 (LILRB2) belong to "Group 1" receptors and recognize a broad range of major histocompatibility complex class I molecules (MHCIs). In contrast, "Group 2" receptors show low similarity with LILRB1/B2, and their ligands remain to be identified. To date, the structural and functional characteristics of Group 2 LILRs are poorly understood. Here we report the crystal structure of the extracellular domain of LILRA5, which is an activating Group 2 LILR expressed on monocytes and neutrophils. Unexpectedly, the structure showed large changes in structural conformation and charge distribution in the region corresponding to the (1). The LILR family has two or four tandem Ig-like extracellular domains and is divided into three functional categories: inhibitory, activating, and secreted receptors (2). The inhibitory LILR receptors have long cytoplasmic tails with two to four immunoreceptor tyrosine-based inhibitory motifs, in which the phosphorylation of tyrosine residues recruits the Src homology 2 domain-containing tyrosine phosphatase-1, transducing negative signals to inhibit activation signals. In contrast, the activating receptors have short cytoplasmic tails lacking immunoreceptor tyrosine-based inhibitory motifs and an arginine residue in the transmembrane region, which binds to negatively charged residues of FcR␥ harboring the immunoreceptor tyrosine-based activation motif. The LILRs are mainly expressed on myelomonocytic cells, although some are also expressed on a wide range of leukocytes. LILRA5 (LIR9/ILT11/CD85f) is expressed as both a membrane-bound activating and a secreted form (3). The membrane-bound form of LILRA5 has two Ig-like domains in the extracellular region with typical features of activating receptors (an arginine in the transmenbrane region and a short cytoplasmic domain), whereas the secreted form only has the extracellular domain. In contrast with LILRB1, which is expressed on a range of leukocytes, the expression of the activating form of LILRA5 has been detected on CD14 ϩ monocytes (3). The expression of LILRA5 has also been detected in neutrophils and monocytes but only at the mRNA level (3). Cross-linking of LILRA5 molecules on monocytes using anti-LILRA5 antibody induced the mobilization of calcium and the secretion of cytokines released in the early stages of inflammatory responses, such as interleukin-
Ig-like transcripts (ILTs) and CD85) are encoded in human chromosome 19q13.4, along with the other Ig-like receptors, including the killer cell Ig-like receptor (KIR) family, FCAR and NKp46 (1) . The LILR family has two or four tandem Ig-like extracellular domains and is divided into three functional categories: inhibitory, activating, and secreted receptors (2) . The inhibitory LILR receptors have long cytoplasmic tails with two to four immunoreceptor tyrosine-based inhibitory motifs, in which the phosphorylation of tyrosine residues recruits the Src homology 2 domain-containing tyrosine phosphatase-1, transducing negative signals to inhibit activation signals. In contrast, the activating receptors have short cytoplasmic tails lacking immunoreceptor tyrosine-based inhibitory motifs and an arginine residue in the transmembrane region, which binds to negatively charged residues of FcR␥ harboring the immunoreceptor tyrosine-based activation motif. The LILRs are mainly expressed on myelomonocytic cells, although some are also expressed on a wide range of leukocytes.
LILRA5 (LIR9/ILT11/CD85f) is expressed as both a membrane-bound activating and a secreted form (3) . The membrane-bound form of LILRA5 has two Ig-like domains in the extracellular region with typical features of activating receptors (an arginine in the transmenbrane region and a short cytoplasmic domain), whereas the secreted form only has the extracellular domain. In contrast with LILRB1, which is expressed on a range of leukocytes, the expression of the activating form of LILRA5 has been detected on CD14 ϩ monocytes (3) . The expression of LILRA5 has also been detected in neutrophils and monocytes but only at the mRNA level (3) . Cross-linking of LILRA5 molecules on monocytes using anti-LILRA5 antibody induced the mobilization of calcium and the secretion of cytokines released in the early stages of inflammatory responses, such as interleukin-1␤, tumor necrosis factor-␣, and interleukin-6 (3). Thus, LILRA5 may modulate CD14 ϩ monocyte function under inflammatory conditions.
The LILR family members can be divided into two groups: "Group 1" (LILRA1/A2/A3/B1/B2) and "Group 2" (LILRA4/ A5/A6/B3/B4/B5) types (4) . Group 1 types have over 70% sequence similarity to LILRB1 and LILRB2, which bind to a broad range of human major histocompatibility complex (MHC) class I molecules (MHCIs: HLA-A, -B, -C, -E, -F, and -G) (5) (6) (7) . Since the crystal structure of the LILRB1-HLA-A2 complex showed that the residues on the MHCI binding site of the Group 1 receptors were well conserved, it is likely that all of the Group 1 receptors have the potential to bind MHCIs. In contrast, Group 2 receptors show less than 60% sequence similarity to LILRB1 and LILRB2 with amino acid substitutions on the MHCI binding site. Preliminary cellular studies (8 -11) have shown that Group 2 LILRs do not bind some MHCI molecules, although ligands for the Group 2 receptors remain to be identified. As a result, it has proved difficult to investigate the Group 2 type LILRs.
Here we report the crystal structure of the whole extracellular domain of LILRA5 at 1.85 Å resolution. This is the first example of a three-dimensional Group 2 LILR structure. The structure showed that the overall structure of LILRA5 resembled the N-terminal two Ig-like domains of LILRB1/B2 previously shown to be responsible for MHCI recognition in these receptors (4) . However, there were large differences in the local structure and surface electrostatic potential of the region corresponding to the MHCI recognition site of LILRB1/B2. The amino acid substitutions responsible for these changes are well conserved in Group 2 LILRs. In addition, surface plasmon resonance and flow cytometric analyses demonstrated that LILRA5 did not recognize all tested MHCIs. Taken together, these results clearly suggested that LILRA5 is not a MHCIrecognizing receptor but binds to unknown ligands to modulate functions of monocytes and neutrophils. By analogy, it seems likely that the other Group 2 LILR members also recognize as yet unidentified ligand(s). The identification of ligands for the Group 2 receptors may provide insight into the mechanisms regulating immune responses.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of LILRA5-A fragment of the gene encoding the LILRA5 extracellular domain was produced by two steps of PCR amplification, using a cDNA library of human peripheral blood mononuclear cells. The forward and reverse primers used to clone the cDNA of LILRA5 were 5Ј-CACCATGGTCTCATCCGTCTG-3Ј and 5Ј-GACT-TGTTTTGTGACGGACTGAG-3Ј, respectively. For introduction of the restriction enzyme sites (NdeI and HindIII), 5Ј-GGA-ATTCCATATGGGGAACCTCTCCAAAGCCAC-3Ј (forward) and 5Ј-TAGGCAAGCTTATGAGACCGGAATCTCCAG-GAG-3Ј (reverse) primers were used. The resultant PCR fragment including the whole extracellular domain (residues with additional N-terminal methionine was digested with the restriction enzymes NdeI and HindIII and ligated into the pGMT7 expression vector (12) . Inclusion bodies of LILRA5 were expressed in Escherichia coli strain BL21(DE3)pLysS and prepared as previously reported for LILRB1 and LILRB2 (7). These were isolated from cell pellets by sonication and were washed with detergent solution containing 0.5% Triton X-100. The purified LILRA5 inclusion bodies were then solubilized with denaturant solution (6 M guanidine hydrochloride, 50 mM MES, pH 6.5, 10 mM EDTA). 1 h prior to refolding, dithiothreitol (2 mM final concentration) was added into the protein solution to reduce disulfide bonds. The solubilized protein solution was diluted slowly into the refolding buffer (0.1 M Tris-HCl, pH 8.0, 0.4 M L-arginine, 2 mM EDTA, 3.73 mM cystamine, 6.37 mM cysteamine) to the final protein concentration of 2 M and stirred for 48 h at 4°C. Then the refolding solution was concentrated with a VIVAFLOW50 system (Sartorius) and an Amicon Ultra concentrator (Millipore). The concentrated LILRA5 solution was loaded on gel filtration column, Superdex 75. Further purification was performed by anion exchange chromatography with ResourceQ (Amersham Biosciences).
Production of Selenomethionyl (SeMet) LILRA5-The inclusion bodies of SeMet derivative LILRA5 were obtained from E. coli strain BL21(DE3)pLysS grown in M9 minimal medium supplemented with 1 mM MgSO 4 , 0.1 mM CaCl 2 , 0.4% glucose, all L-amino acids except methionine, and 25 mg/liter SeMet. The SeMet LILRA5 was refolded and purified in the same way as the native protein described above.
Crystallization and Data Collection-Purified SeMet LILRA5 (20 mM Tris, pH 9.0, 50 mM NaCl) was concentrated to 10 mg/ml. An initial crystallization trial was performed using the crystallization screening kits, Crystal Screen I&II (Hampton Research) and Wizard I&II (Emerald Biostructures). 0.2 l of protein solution was mixed in a 1:1 ratio with the crystallization reservoir solution on the Intelli-Plate (Art Robbins Instruments) using an autocrystallization setup system for sitting drop vapor diffusion, HYDRA-Plus1 (Apogent Discoveries). Square rod-type crystals were obtained in the condition of Crystal Screen II-48 (0.1 M Bicine, pH 9.0, 10% polyethylene glycol 20000, and 2% dioxane) at 20°C. Crystals suitable for data collection were grown from 2-l hanging drops containing the same protein/condition mixture. Multiwavelength anomalous dispersion data were collected with an ADSC Quantum 315 CCD detector at the beamline BL41XU of SPring-8 (Harima, Japan). Data collection was carried out at 100 K with crystals soaked in the reservoir solution containing 20% ethylene glycol. The diffraction data were processed and scaled with the HKL2000 program package (Table 1) .
Structure Determination and Refinement-The initial phasing and subsequent density modification were performed with programs the SOLVE (13) and RESOLVE (14) . Automated chain tracing conducted with ARP/wARP (15) placed 115 of 196 residues in electron density. Further model building was done with LAFIRE (available on the World Wide Web at altair. sci.hokudai.ac.jp/g6/Research/Lafire_English.html). Subsequent manual model building and refinement were carried out using the programs O (16), CNS (17) , and Refmac5 (18) . The final model contained 180 of 196 residues (93 of 95 in domain 1 and 87 of 101 in domain 2) and 105 water molecules, with an R-factor of 23.4% (R free ϭ 26.9%). Residues 1 and 2, 106 -116, and 136 -138 were disordered. 91.8% of total residues were in the most favored regions, and 0% were in the disallowed regions of the Ramachandran plot. Ramachandran plot and secondary structure assignments were generated with PROCHECK (19) . Superimposition and root mean square difference calculation were performed using Swiss-Pdbviewer. In order to analyze the interdomain contacts and buried surface areas, D1 was defined as residues 1-96, and D2 was defined as residues 97-196, based on the structure. Interdomain contact residues were identified using the program CONTACT (41) . Buried surface areas were calculated with the program NACCESS (available on the World Wide Web at wolf.bms.umist.ac.uk/naccess/) with a 1.4-Å probe radius. Figures were prepared using PyMOL (available on the World Wide Web at pymol.sourceforge.net/) and GRASP (20) .
Surface Plasmon Resonance Analyses-Surface plasmon resonance experiments were performed using a BIAcore2000 TM (BIAcore AB, St. Albance, UK). The biotinylated human MHC class I molecules were prepared as described previously (7) and immobilized on the research grade sensor chip CM5 (BIAcore AB) on which streptavidin was covalently immobilized using the amine coupling method. The LILRA5 and LILRB1 solution was buffer-exchanged to HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% surfactant P20), and LILRA5 (or LILRB1) solution was flowed over at a rate of 10 l/min.
Flow Cytometric Analysis for Binding of LILRA5 to HLACw4-transfected 721.221 Cells-We constructed a vector containing LILRA5 fused to a C-terminal biotin ligase (BirA) recognition tag (GSLHHILDAQKMVWNHR). Tagged LILRA5 was refolded and purified as the wild type protein. Biotinylated LILRA5 was prepared as described previously (7) . The LILRA5 tetramer was produced by incubation of biotinylated LILRA5 with phycoerythrin-conjugated streptavidin (Molecular Probes) for 15 min on ice. LILRB1 tetramer was prepared in the same manner. HLA-Cw4-transfected 721.221 cells (kindly provided by Dr. P. Parham) were also produced. Cells were incubated with either LILRB1 or LILRA5 tetramer for 1 h on ice. Untreated control cells were incubated with phycoerythrin-conjugated streptavidin. Subsequently, stained cells were analyzed by EPICS ALTRA (Beckman Coulter). Cell surface expression of HLA-Cw4 was monitored by 0.01 mg of fluorescein-labeled W6/32 anti-HLA monoclonal antibody (H-199; Leinco Technologies) or fluorescein-labeled mouse IgG2a (I-106; Leinco Technologies).
RESULTS AND DISCUSSION
Crystallization and Structural Determination of LILRA5 Extracellular Domain-The whole extracellular domain of LILRA5 (residues 1-196) was overexpressed in E. coli as inclusion bodies and renatured by dilution refolding (7). One major peak was obtained from gel filtration and further purified by ion exchange chromatography. Crystals of the LILRA5 protein (space group was primitive orthorhombic (P2 1 2 1 2 1 ), and unit cell parameters were a ϭ 28.0 Å, b ϭ 58.5 Å, c ϭ 131.2 Å) were obtained in 0.1 M HEPES, pH 7.5, 20% polyethylene glycol 4000, and 10% isopropyl alcohol, and the data set was collected to the resolution limit of 2.2 Å at SPring-8. It proved impossible to solve the structure of LILRA5 by molecular replacement using the structure of either LILRB1 or LILRB2 as a search probe. Therefore, we produced SeMet derivative protein in order to perform multiwavelength anomalous dispersion analysis. The SeMet derivative of LILRA5 was refolded, purified, and concentrated using a protocol similar to that described for the native protein. It was not possible to crystallize the SeMet protein in similar conditions to the native protein, but crystals were obtained in 0.1 M Bicine, pH 9.0, 10% polyethylene glycol 20000, and 2% dioxane. The crystal structure of the extracellular domain of LILRA5 was determined in the space group of P2 1 2 1 2 1 to 1.85 Å resolution by the multiwavelength anomalous dispersion method (details given under "Experimental Procedures" and in Table 1 ). The refined structure of the LILRA5 extracellular domain included two Ig-like domains (domain 1 (D1; residues 3-96) and domain 2 (D2; residues 100 -195)), with a short linker connecting the two domains (residues 97-99) (Fig. 1, A and B) . The AB (residues 106 -116) and CCЈ (residues 136 -138) loops of D2 were disordered (Fig. 1, A and  C) . The average B-factor of D2 (46.0 Å 2 ) was higher than that of domain 1 (D1) (24.3 Å 2 ), which may be due to the relatively loose packing of D2 in the crystal.
Overall Structure-The amino acid sequence identities among the other Ig-like receptors encoded within the LRC region (hereafter, designated as the LRC receptors), such as LILRA5, KIR, NKp46, and Fc␣R, are 35-41%, lower than those among LILR family receptors (Fig. 2) . However, the overall structure of LILRA5 closely resembled that of the LRC recep- 2 ). The folding topology of LILRA5 was similar but distinct from LILRB1 and B2 (detailed differences are described below). Rather the topology of D1 and D2 domains was essentially the same as NKp46 and KIR2DLs, respectively, despite the low sequence identities between these receptors and LILRA5 (Fig.   2 ). Similar to the other LRC receptors, the first ␤-strand (A strand) in D1 of LILRA5 is split into two shorter strands (A and AЈ) by a cis-proline (Pro 12 ) and shared between the two ␤-strands (B and G strands). However, residues 106 -116 of D2, which corresponds to the AЈ strand of D1 in the other LRC receptors, was disordered. The insertion of the cis-proline residue (Pro 194 ) distorted the G strand in D2, which prevents the AЈ strand from making hydrogen bonds to the G strand as observed in D1 of LILRA5 and the other LRC receptors (Fig.  1C) . Thus, this loop is more flexible than the equivalent region in the other LRC receptors. Since the predicted N-linked glycosylation site (Asn 116 ) was located on the disordered AB loop in D2, the attached sugar moiety might be expected to be very mobile (Fig. 1A) . The polyproline II helix located in the FG loop of each domain was observed in LILRA5, as in KIRs, NKp46, Fc␣R, and the cytokine receptors (28 -31) . LILRA5 included only one 3 10 helix between the E and F strands in D1, whereas the other structurally characterized LILRs, LILRB1 and LILRB2, contain three and five 3 10 helices, respectively.
Comparison of LRC Receptor Ligand Binding Sites-
The amino acid sequence identity between LILRA5 and LILRB1/ LILRB2 (59%/55%) is lower than those among the Group 1 receptors (LILRA1/A2/A3/B1/B2) (79 -88%) (Fig. 2) , but still high enough to show basically the same overall structural fold as observed above. Unexpectedly, however, LILRA5 receptor has significant structural differences compared with LILRB1 (4) and LILRB2 (27) . First, there is a ␤ strand, the CЈ strand in D1 of LILRA5, where the LILRB1 and LILRB2 structures have a 3 10 helix (Fig. 3A, left) . It is of note that this region (amino acid residues 41-49) is directly involved in the recognition of the ␣3 domain of MHCIs in LILRB1 and LILRB2 (4). 5 These changes would be likely to inhibit MHCI binding to LILRA5 (Fig. 3) (Fig. 3C, left) . On the contrary, LILRA5 does not have hydrophobic residues, such as Asp 47 , Asn 50 , and Ser 61 (Fig. 3C, right) , possibly preventing the 3 10 helix formation observed in the LILRB1 structure, but instead rendering the ␤-sheet formation and providing the hydrophobic deep pocket (red dotted circle in Fig. 3C, right) . Furthermore, the combination of Pro 43 and Pro 45 in LILRA5 (only Pro 45 in LILRB1) enabled the acute bent turn to achieve the opposite direction from C to CЈ strands forming the extended ␤-sheet (Fig. 3C, right) . Whereas the continuous 3 10 helix structure in LILRB1 is lined by Leu 54 participating in the hydrophobic core described above, Pro 54 in LILRA5 stabilizes the turn structure from CЈ to E strands (Fig.  3C, left) . These residues characteristic in LILRA5 are well conserved in Group 2 LILR members (Fig. 3B) . Therefore, they probably adopt the sheet structure similar to LILRA5, supporting the idea that Group 2 LILRs do not have any binding ability to MHCIs.
Second, LILRA5 has the D strand interacting with a portion of the E strand in the D2 domain, not observed in LILRB1 and LILRB2 but found in KIRs (Fig. 3A, right; (Fig. 2) . These strands do not directly interact with the MHCIs. As yet, it is uncertain whether this structural difference has an effect on ligand recognition. However, the neighboring region, including the BC and FG loops, is positively charged in LILRA5 (Arg 124 , Arg 126 , Arg 177 , and His 179 ) with some hydrophobic residues (Leu 125 , Leu 148 , Phe 154 ), in contrast with LILRB1/B2 and KIRs, where the equivalent region is negatively charged (Fig. 4, also discussed below) . This region is responsible for the receptor recognition toward the peptide-binding groove (KIRs) or ␤2m domain (LILRB1/B2) of MHCIs. This surface composition of LILRA5 is significantly distinct from KIRs and LILRB1/B2 and thus again probably inhibits the MHCI binding.
Among the LRC receptors, structures of LILRB1 (4), KIRs (32, 33) , and Fc␣R (25) have been determined in complex with their ligands. The comparison of the sequence of the ligand binding sites between these receptors and LILRA5 shows that the residues are not well conserved between these receptors and LILRA5 (Fig. 2) . Electrostatic potential maps of the molecular surface clearly show the different charge distributions of LILRA5 compared with LILRB1, KIRs, and Fc␣R, as partly described above (Fig.  4) . LILRB1 has strongly negatively and positively charged regions, both of which are involved in the MHCI binding (␤2m and ␣3 domain). In addition, KIRs also contain a large negatively charged area crucial for MHCI binding (peptide-binding groove). However, in contrast with the above receptors, small negative and positive patches were dispersed on the surface of LILRA5, and a few hydrophobic areas were observed (Fig. 4) . These features indicated that LILRA5 are likely to recognize as yet unidentified ligands. This suggestion is consistent with the biochemical study showing that LILRA5 does not interact with any of the tested MHCIs, as described below. Although surface charge distribution and less hydrophobic characteristics described above do not provide any potential candidate ligands, it is possible that LILRA5 forms a charge-complementary interface with unknown ligands, similarly to those of KIR-MHC, LILRB1-MHC, and Fc␣R-Fc␣ complexes, associated with low affinity and fast kinetics.
LILRA5 Does Not Recognize Classical or Nonclassical MHC Class I Molecules-Binding analysis was performed using surface plasmon resonance to elucidate the functional characteristics of LILRA5. C-terminal biotinylated classical and nonclassical MHCIs (HLA-A, -B, -C, -E, and -G) were immobilized on the sensor chip, and LILRA5 or LILRB1 (as a control) solution was flowed over. LILRB1 interacted with all MHCIs at dissociation constants of 2.1-7.2 M (Fig. 5A) , as observed previously (7) . In contrast, LILRA5 did not interact with any classical or nonclassical MHCI tested (Fig. 5A) . Furthermore, we prepared the biotinylated LILRA5 molecules to make a LILRA5 tetramer-phycoerythrin conjugate for flow cytometric analysis. Flow cytometric analysis showed that in contrast to LILRB1, the LILRA5 tetramer could not bind to HLA-Cw4-transfected 721.221 cells (Fig. 5B) . These results indicated that LILRA5 did not bind to MHCIs in solution or at the cell surface, strongly suggesting that LILRA5 binds to non-MHCI ligands if any.
Implications for Ligand Binding of Group 2 LILR-As described above, the amino acid sequence of the D1 domain of LILRA5 was similar to those of other Group 2 receptors, such as LILRB3 (LIR3/ILT5/CD85a; 81%) and LILRB4 (LIR5/ILT3/CD85k; 83%), whose ligands are also yet to be identified (8) . LILRB3 has been recently identified as a novel inhibitory receptor of human basophils (34) , whereas LILRB4 is known to be expressed on human monocyte and dendritic cells. LILRB4 is up-regulated together with LILRB2 on these antigen-presenting cells, rendering the cells tolerogenic after exposure to CD8 ϩ CD28 Ϫ alloantigen-specific T suppressor cells (35) . In this case, these inhibitory receptors recognize their ligands on the T suppressor cells and mediate the negative signal, resulting in the inactivation of the DCs. Furthermore, the recent report of KimSchulze et al. (36) demonstrated that the recombinant LILRB4 binds to CD4 ϩ T cells stimulated with allogeneic antigen-presenting cells, indicating that the expression of ligand(s) for Group 2 receptor LILRB4 is controlled according to T cell regulation. Together with previous reports, our current results indicate that LILRA5 as well as Group 2 LILRs have similar structural characteristics to be unable to bind MHCIs but rather recognize non-MHCI ligand(s). It cannot be completely ruled out that Group 2 LILRs can bind to special peptide-bound or unusual forms of MHCIs. However, the LILRB4 ligand(s) expressed on activated T cells would probably be non-MHCIs and/or relative molecules, which can probably be ligands for other Group 2 LILRs. On the other hand, the LILR family was reported to be involved in lepromatous leprosy disease progression by infection of Mycobacterium leprae (37) . The elevated expression of Group 1 LILRs (LILRA2 and LILRA3) as well as Group 2 LILRs (LILRB3 and LILRB5) is observed in the lepromatous leprosy patients. Although Group 2 LILRs may simply regulate immune response in infectious lesions by binding to self-ligands, it may also be possible that bacterial ligands for Group 2 LILRs exist. Similarly, Group 2 LILR ligands may include such viral proteins as observed for the Ly49H receptor (38) . Further experiments are required to identify the ligands for Group 2 LILRs and thus provide a new mechanism for the LILRA5-mediated monocyte/neutrophil regulation.
Our previous association study between polymorphisms of Group 1 LILR, LILRB1, and rheumatoid arthritis in Japanese subjects demonstrated that LILRB1 is highly polymorphic, and one of those haplotypes is associated with the susceptibility to rheumatoid arthritis in HLA-DRB1 shared epitope-negative subjects (39) . Interestingly, as pointed out by the review of Brown et al. (2) , the cross-linking of LILRA5 ϩ on the surface of monocytes confers calcium flux and secretion of proinflammatory cytokines interleukin-1␤ and tumor necrosis factor-␣, which are mainly produced by macrophages in the rheumatoid arthritis synovial fluid (40) . Because LILRA5 is expressed not only as a membrane-bound form but as a secreted one, LILRA5 signaling is expected to be modulated by the ratio of these isoforms. Therefore, the elucidation of the LILRA5 signaling pathway, especially the identification of LILRA5 ligand(s), will give new insights to the molecular mechanism of the immunological tolerance and the pathogenesis of inflammatory diseases.
Conclusion-Here we report the first structure of a Group 2 LILR family member, LILRA5. The crystal structure of LILRA5 exhibits distinct features of both structural conformations and surface electrostatic potential from related LRC-encoded receptors, such as LILRB1/B2, KIRs, Fc␣R, and NKp46. The key amino acids responsible for these characteristics are well conserved in Group 2 LILRs. The surface plasmon resonance binding and cell staining studies demonstrate that LILRA5 does not bind to any of the tested classical and nonclassical MHCIs. Taken together, these data suggest that LILRA5 as well as Group 2 LILRs could play a novel role in immune regulation by recognizing unknown ligand(s) other than MHCIs.
